Metatron Capital SICAV’s Charles River Laboratories CRL Stock Holding History

Metatron Capital SICAV’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	$980K	Buy	+2,600	New	+$1.01M	0.93%	27

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metatron Capital SICAV's CRL Position: Q4 2021 in Review

Metatron Capital SICAV opened a new position in Charles River Laboratories (CRL) in Q4 2021: 2,600 shares worth $980K. The stake represents 0.93% of the portfolio and ranks #27 among its holdings.

707 funds tracked by Wall St. Rank hold CRL as of Q4 2021.

Metatron Capital SICAV held 2,600 shares of Charles River Laboratories worth $980K as of Q4 2021.
Charles River Laboratories was a new Metatron Capital SICAV position in Q4 2021.
Charles River Laboratories made up 0.93% of Metatron Capital SICAV's portfolio in Q4 2021, its #27 holding.
707 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2021.

Based on Metatron Capital SICAV's 13F filing for Q4 2021, filed 15 Feb 2022.